DEXOXADROL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H23NO2
Molecular Weight	309.4021
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]1(COC(O1)(C2=CC=CC=C2)C3=CC=CC=C3)[C@]4([H])CCCCN4

InChI

InChIKey=HGKAMARNFGKMLC-RBUKOAKNSA-N

InChI=1S/C20H23NO2/c1-3-9-16(10-4-1)20(17-11-5-2-6-12-17)22-15-19(23-20)18-13-7-8-14-21-18/h1-6,9-12,18-19,21H,7-8,13-15H2/t18-,19+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C20H23NO2
Molecular Weight	309.4021
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3253423 | https://www.ncbi.nlm.nih.gov/pubmed/16719812

Dexoxadrol is a sigma receptor agonist. Dexoxadrol, the D-isomer of dioxodrol, which produces PCP-like behavioural effects and displaces bound [3H]PCP, was a potent blocker of the PCP-sensitive, voltage-gated K+ channel. Dexoxadrol was developed as analgesics for use in humans, however, severe side effects including psychotomimetic effects, unpleasant dreams and aberrations stopped the clinical evaluation of dexoxadrol. Dexoxadrol is a NMDA receptor antagonist, which possesses high affinity to the phencyclidine binding site within the NMDA receptor associated ion channel.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glutamate NMDA receptor 46 Target ID: CHEMBL1907608 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2747847 \| https://www.ncbi.nlm.nih.gov/pubmed/16169732	Antagonist 2778		104.0 nM [Ki]
Glutamate NMDA receptor; GRIN1/GRIN2A 3 Target ID: CHEMBL1907604 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26430967	Antagonist 2778		19.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alcoholism 19 Sources: https://www.ncbi.nlm.nih.gov/pubmed/5441096	Primary		Phase I 428	Unknown Approved Use Unknown
Pain 614 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4187619 https://www.ncbi.nlm.nih.gov/pubmed/14270339	Primary		Phase I 428	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
20 mg single, oral (unknown) Studied dose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/14270339	healthy, ADULT n = 74 Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/14270339	Other AEs: psychosis... Other AEs: psychosis (5 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/14270339

AEs

AE	Significance	Dose	Population
psychosis	5 patients	20 mg single, oral (unknown) Studied dose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/14270339	healthy, ADULT n = 74 Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/14270339

Sourcing

Vendor/Aggregator	ID	URL
AK Scientific	SYN5508	https://aksci.com/item_detail.php?cat=SYN5508
AOBIOUS INC	AOB5315	http://aobious.com/aobious/search?search_query=AOB5315
Alfa Chemistry	162111	http://www.alfa-chemistry.com/search.aspx?q=162111
Alfa Chemistry	ACM4792181	http://www.alfa-chemistry.com/search.aspx?q=ACM4792181
Hairui	HR149457	http://www.hairuichem.com/en/product/search.do?q=HR149457
Hairui	HR149520	http://www.hairuichem.com/en/product/search.do?q=HR149520
KeyOrganics	AS-16845	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-16845
MolPort	MolPort-044-181-434	https://www.molport.com/shop/molecule-link/MolPort-044-181-434
MuseChem	I006462	https://www.musechem.com/product/I006462.html
MuseChem	I012683	https://www.musechem.com/product/I012683.html
TimTec	ST50556819	http://www.echemstore.com/catalogsearch/result/?q=ST50556819
eMolecules	85147611	https://orderbb.emolecules.com/search/#?query=85147611
mcule	MCULE-3791881888	https://mcule.com/MCULE-3791881888/
mcule	MCULE-4804227183	https://mcule.com/MCULE-4804227183/
mcule	MCULE-9801028073	https://mcule.com/MCULE-9801028073/

PubMed

Title	Date	PubMed
Structure-affinity relationship studies of non-competitive NMDA receptor antagonists derived from dexoxadrol and etoxadrol.	2005 Dec 15	16169732
Relationships between the structure of dexoxadrol and etoxadrol analogues and their NMDA receptor affinity.	2006	16719812
Synthesis and NMDA-receptor affinity of 4-oxo-dexoxadrol derivatives.	2006 Sep 1	16750371

Patents

Sample Use Guides

In Vivo Use Guide

In hospitalized cancer and arthritic patients dexoxadrol at 10 mg or 20 mg dosage in combination with 600 mg of acetylsalicylic acid has analgesic properties significantly superior to either acetylsalicylic acid (600 mg) or codeine (60 mg) alone. Administration of dexoxadrol (20 mg, orally, twice daily) to 128 patients with severe pain gave complete relief to 50 % and partial relief to 28 % of the patients.

Route of Administration: Oral

In Vitro Use Guide

Dexoxadrol (10 uM) selectively blocked the secondary components of the synaptic response in rat hippocampal slices.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:04:21 UTC 2023` Edited by `admin` on `Fri Dec 15 15:04:21 UTC 2023`
Record UNII	JY5N9F45AG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DEXOXADROL

Official Name

English

(+)-2-(2,2-DIPHENYL-1,3-DIOXOLAN-4-YL)PIPERIDINE

Systematic Name

English

PIPERIDINE, 2-((4S)-2,2-DIPHENYL-1,3-DIOXOLAN-4-YL)-, (2S)-

Systematic Name

English

(+)-.ALPHA.-DIOXADROL

Common Name

English

DEXOXADROL [HSDB]

Common Name

English

dexoxadrol [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C241